Traditional Chinese Herbal Formula Eases Insulin Resistance and Ovarian Dysfunction in PCOS Mouse Model

Why this matters: PCOS affects roughly 15% of women worldwide, and insulin resistance (IR) is reported in up to 75% of patients. IR drives hyperinsulinemia, raises free testosterone, and impairs follicle maturation and ovulation. Current treatment cannot cure PCOS, so there is interest in multi-target options such as traditional Chinese medicine. Local IR inside the ovary, particularly in granulosa cells that nourish the oocyte, is poorly understood.

What was studied: The team examined Cangfu Daotan Decoction (CDD), a ten-herb formula that includes Atractylodes, Cyperus, Poria, tangerine peel, Pinellia and licorice. First, they used UPLC-HRMS to profile the extract and the serum of rats given CDD, which identified 15 blood-absorbed compounds among 44 labeled peaks. Network pharmacology and molecular docking then predicted targets, yielding 94 genes overlapping with PCOS and IR, with STAT3 binding several CDD compounds strongly. For in vivo work, C57BL/6 mice received letrozole plus a 60% high-fat diet for 21 days to model PCOS-IR. Successfully modeled mice were treated for 14 days with low-dose (12.48 g/kg/day) or high-dose (37.44 g/kg/day) CDD, with measurements of estrous cycles, hormones (LH, FSH, AMH, E2, testosterone, SHBG, insulin), glucose tolerance, ovarian histology, and pathway expression by qPCR and Western blot. In vitro, human KGN granulosa-like cells were cultured with follicular fluid from women with PCOS-IR (versus controls) to mimic the disease environment. They were then treated with CDD-containing serum, and STAT3 and FOXO4 were knocked down by siRNA.

Key results: According to the abstract, CDD improved ovarian function and reduced insulin resistance in PCOS-IR mice. In KGN cells under PCOS-IR conditions, CDD enhanced glucose intake. In both models, CDD significantly suppressed activation of the IL6/JAK2/STAT3/FOXO4 signaling pathway. The authors conclude that CDD may act through this axis.

Implications: The work suggests a plausible mechanism by which a traditional formula could address ovarian inflammation and local insulin resistance. It also adds IL6/JAK2/STAT3 signaling as a candidate therapeutic target in PCOS-IR, building on the group's earlier PKP3/ERCC1/MAPK findings.

Caveats: The supplied full text cuts off before the detailed results, so effect sizes, statistics, and the exact outcomes of the knockdown experiments could not be verified here. The evidence is animal and cell-line based. The letrozole model reproduces only part of human PCOS, KGN cells derive from a granulosa cell tumor, and human follicular fluid came from only ten patients per group. The doses were also far above what humans take in terms of raw herb weight. Whether CDD works in women is untested.